<DOC>
	<DOCNO>NCT01875822</DOCNO>
	<brief_summary>Current evidence suggest schizophrenia serious complex psychiatric disorder , continue challenge mental health professional search good treatment option community . In present study , investigator hypothesize patient diagnose schizophrenia , adjunct treatment Curry extract plant label botanist Curcuma Longata , formulate Super-Curcumin @ , would bring :1 ) positive behavioral change area socialization , emotional well-being , verbal communication motivation ; 2 ) improvement measure memory . Throughout study , proprietary product , Super-Curcumin @ consist Curcumin C-3 complex combine black pepper extract Bioperine boost effect Curcumin . The study develop examine whether Curcumin 's interaction two major signal pathway brain regulate brain-behavior : epigenetic signal ( histone modification ) anti-inflammatory signal ( inducible nitric oxide synthetase ) preclinical model translate beneficial effect treatment schizophrenia .</brief_summary>
	<brief_title>Open-label Study Curcumin C-3 Complex Schizophrenia</brief_title>
	<detailed_description>Detailed Description : The overall objective study evaluate whether standardized proprietary formulation curcumin [ Super Curcumin @ : C-3 Complex @ Bioperine @ ) manufacture American Finest Inc. NJ USA ] extract curry plant ( Curcuma Longata ) , improve negative symptom cognitive impairment patient diagnose schizophrenia determine response rate negative symptom 16 week . Response rate define positive change minimum 30 % high baseline score measure 16 week . Negative symptom refer cluster symptom apathy , alogia , blunt affect lack motivation affect severely way individual function community large . In study , investigator propose test hypothesize Super curcumin @ efficacious safe combine standard antipsychotic drug cohort patient diagnose schizophrenia . Throughout study , proprietary product ( Super curcumin @ ) use . Supercurcumin @ consist primary medicinally active ingredient , Curcumin C-3 Complex , combination Bioperine @ , metabolic enhancer extract black pepper , order increase systemic bioavailability curcumin C-3 complex . For oral formulation Super- curcumin @ : 1 gm-capsule 1 gm curcumin C-3 complex 5 mg Bioperine @ . The study protocol consist recruit subject diagnose schizophrenia would receive either 1 gm 4 gm Super-Curcumin @ give orally daily 16 week , negative symptom cognition . For assess safety tolerability Supercurcumin @ , study protocol require patient would monitor regularly vital sign : blood pressure , pulse , body weight , routine blood chemistry comprehensive adverse event profile ( Treatment Emergent Adverse Events checklist ) include AIMS ( Abnormal Involuntary Movement Scale ) . At baseline regular interval throughout 16-week treatment period , standardized measure negative positive symptom neurocognition would administer examine efficacy Curcumin C-3 complex schizophrenia . For analyse result , within-subject pre- post-treatment response would subject statistical procedure evaluate whether Super-Curcumin @ ameliorate persistent negative symptom cognitive deficit schizophrenia .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>Male female : DSMIV ( Diagnostic Statistical Manual TR version ) Schizophrenia Male Female , age 1865 yr SANS ( Scale Negative Symptoms Schizophrenia ) &gt; 30 Stable antipsychotic dosage least 1 month Current Substance use Disorder except Nicotine dependence Regular Use NSAID ( nonsteroidal antiinflammatory drug ) cancer History Recent myocardial infarction Unstable angina , untreated severe hypertension Poorly control diabetes mellitus Type I Type II Chronic liver &amp; gallbladder disease Recent GERD ( Gastroesophageal Reflux Disorder ) Pregnancy breastfed . Allergic reaction Curcumin Neurological disorder : epilepsy , stroke Hamilton Depression Scale Hamilton Depression Rating Scale ( HAMD17 item ) &gt; 24</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Curcumin</keyword>
	<keyword>Epigenetics</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Nitric Oxide synthetase</keyword>
	<keyword>cognition</keyword>
	<keyword>negative symptom</keyword>
</DOC>